Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erlotinib in Advanced Pancreatic Cancer

Erlotinib in Advanced Pancreatic Cancer Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. erlotinib study, these did not achieve statistical significance, per- haps in part because of underpowering of those studies. It is only A Viewpoint by Andrew H. Ko when one looks at the hazard ratio for the PA 3 trial – a reflection Division of Hematology/Oncology, San Francisco of differences between the two arms over the entire course of study Comprehensive Cancer Center, University of California, San treatment – that the survival advantage became more clear cut. Francisco, California, USA This fact, as well as the generally minimal toxicity profile seen with gemcitabine plus erlotinib, provides further justification for Since the approval of gemcitabine for advanced pancreatic considering this combination as a reasonable option in advanced cancer in 1997, attention has turned toward evaluating whether pancreatic cancer. gemcitabine in combination with other therapeutic agents might A number of questions remain unanswered. First and foremost, confer further improvements in patient outcomes. A number of does the combination of gemcitabine/erlotinib now become the de multicenter, randomized, phase III studies have since been con- facto standard of care for first-line therapy and the new http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Erlotinib in Advanced Pancreatic Cancer

American Journal of Cancer , Volume 5 (1) – Aug 10, 2012

Erlotinib in Advanced Pancreatic Cancer

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. erlotinib study, these did not achieve statistical significance, per- haps in part because of underpowering of those studies. It is only A Viewpoint by Andrew H. Ko when one looks at the hazard ratio for the PA 3 trial – a reflection Division of Hematology/Oncology, San Francisco of differences between the two arms over the entire course of study...
Loading next page...
 
/lp/springer-journals/erlotinib-in-advanced-pancreatic-cancer-rkveLEirQW
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. erlotinib study, these did not achieve statistical significance, per- haps in part because of underpowering of those studies. It is only A Viewpoint by Andrew H. Ko when one looks at the hazard ratio for the PA 3 trial – a reflection Division of Hematology/Oncology, San Francisco of differences between the two arms over the entire course of study Comprehensive Cancer Center, University of California, San treatment – that the survival advantage became more clear cut. Francisco, California, USA This fact, as well as the generally minimal toxicity profile seen with gemcitabine plus erlotinib, provides further justification for Since the approval of gemcitabine for advanced pancreatic considering this combination as a reasonable option in advanced cancer in 1997, attention has turned toward evaluating whether pancreatic cancer. gemcitabine in combination with other therapeutic agents might A number of questions remain unanswered. First and foremost, confer further improvements in patient outcomes. A number of does the combination of gemcitabine/erlotinib now become the de multicenter, randomized, phase III studies have since been con- facto standard of care for first-line therapy and the new

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.